Nkarta reports Q3 net loss $25.6M; cash $278.4M; extends runway into 2026

Nkarta, Inc.

2023-Q3 EPS reported -$1.83

Net loss of $25.6M ($0.52 per share) for Q3 2023; R&D expenses $22.2M, G&A $7.1M.
Cash and investments $278.4M as of Sep 30, 2023; cost containment extends cash runway into 2026.
FDA cleared IND for NKX019 in lupus nephritis; first patient dosing expected H1 2024.
Workforce reduced ~10%; operations centralization and manufacturing optimization underway.
Clinical data updates in 2024: NKX101 AML, NKX019 NHL compressed dosing, LN.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Nkarta, Inc. reported financial results for the third quarter ended September 30, 2023.

Period: the third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 9, 2023, Nkarta, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the third quarter ended September 30, 2023.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Nkarta, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-062019

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.